Severity of depression and response to antidepressants and placebo: an analysis of the food and drug administration database / Arif Khan en Journal of Clinical Psychopharmacology, Año 2002 - Vol. 22 - No. 2 (Febrero)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2002 - Vol. 22 - No. 2 (Febrero) . - pp. 40-45 Título : Severity of depression and response to antidepressants and placebo: an analysis of the food and drug administration database Tipo de documento: texto impreso Autores: Arif Khan, Autor ; Robyn M. Leventhal, Autor ; Shirin R. Khan, Autor Fecha de publicación: 2023 Artículo en la página: pp. 40-45 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antidepresivos, Ensayos Clínicos, Trastorno Depresivo. Resumen: Some studies suggest that more severely ill patients with depression respond well to antidepressants and poorly to placebo, whereas those who are mildly ill respond equally well to antidepressants and placebo. This notion has implications for the design of clinical trials. To further assess and substantiate these putative predictors of antidepressant and placebo response, we assessed the Food and Drug Administration database of 45 phase II and III antidepressant clinical trials. Link: ./index.php?lvl=notice_display&id=31092 [artículo] Severity of depression and response to antidepressants and placebo: an analysis of the food and drug administration database [texto impreso] / Arif Khan, Autor ; Robyn M. Leventhal, Autor ; Shirin R. Khan, Autor . - 2023 . - pp. 40-45. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2002 - Vol. 22 - No. 2 (Febrero) . - pp. 40-45 Palabras clave: Antidepresivos, Ensayos Clínicos, Trastorno Depresivo. Resumen: Some studies suggest that more severely ill patients with depression respond well to antidepressants and poorly to placebo, whereas those who are mildly ill respond equally well to antidepressants and placebo. This notion has implications for the design of clinical trials. To further assess and substantiate these putative predictors of antidepressant and placebo response, we assessed the Food and Drug Administration database of 45 phase II and III antidepressant clinical trials. Link: ./index.php?lvl=notice_display&id=31092

---

1 (1 - 1 / 1)